药物不良事件导致停药的患者中更常见的获得比那些接受新青二萘夫西林。

文章的细节

引用

复制到剪贴板

谢里丹KR Viehman是的,Oleksiuk LM,拜尔斯柯,他P, RK Falcione BA、盾牌

药物不良事件导致停药的患者中更常见的获得比那些接受新青二萘夫西林。

Antimicrob代理Chemother。2016年4月22日,60 (5):3090 - 5。doi: 10.1128 / AAC.03122-15。打印2016年5月。

PubMed ID

26976858 (在PubMed

]

文摘

苯唑西林萘夫西林和在临床实践中交替使用,但很少有研究评估这两个代理的安全。我们的目标是比较苯唑西林萘夫西林的耐受性差,住院病人。我们进行了一项回顾性队列研究的病人12克/天苯唑西林萘夫西林或至少24小时。包括二百二十四名患者。患者基线特征及并发症相似萘夫西林(n = 160)和那些接受新青二(n = 64)。低钾血,定义为一个钾水平/ = 0.5更易/升减少从基线水平,更频繁地发生在病人萘夫西林(分别为51%,20%,56%)比那些收到新青二(分别为17%、3%和34%;P < 0.0001, P = 0.0008, P = 0.005)。多元逻辑回归分析,收到萘夫西林是一个独立的预测严重低血钾(优势比[或]= 6.74;95%可信区间(CI), 1.46 - 31.2;P = 0.02)。的肝毒性组没有差异; however, acute kidney injury occurred more commonly with nafcillin than with oxacillin (18% versus 6%; P = 0.03). Overall, 18% of patients who received nafcillin discontinued therapy prematurely due to adverse events, compared to 2% of patients who received oxacillin (P = 0.0004). Nafcillin treatment is associated with higher rates of adverse events and treatment discontinuation than oxacillin among hospitalized adult patients. These findings have important implications for patients in both inpatient and outpatient settings, particularly patients who require long-term therapy and cannot be monitored routinely. Future randomized controlled studies evaluating the efficacy, costs, and tolerability of nafcillin versus oxacillin are warranted.

DrugBank数据引用了这篇文章

药物

萘夫西林